Company Overview and News

1
Gifts That Keep On Giving: Is Backdating Back? : TheCorporateCounsel.net Blog

2018-01-03 thecorporatecounsel.net
Last month, the WSJ published an investigative report that suggested that hundreds of corporate insiders frequently had uncanny timing when it came to gifts of company stock.

 
Unilife SC 13G/A (Passive Acquisition of More Than 5% of Shares)

2017-08-02 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)*     UNILIFE CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 90478E103 (CUSIP Number) July 24, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐

 
Unilife SC 13G/A (Passive Acquisition of More Than 5% of Shares)

2017-08-02 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)*     UNILIFE CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 90478E103 (CUSIP Number) July 24, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐

 
Ampoules and Syringes Market, Plastic Ampoules, Cyclic Olefin Copolymers, and Cyclic Olefin Polymers; Syringe Product Type - Polymer Syringes and Glass Syringes - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

2017-07-10 prnewswire
LONDON, July 10, 2017 /PRNewswire/ -- Global Ampoules and Syringes Market: Overview This report provides forecast and analysis of the ampoules and syringes market on the global and regional level. The study provides historic data of 2015 along with forecast from 2016 to 2024 based on volume (Mn Units) and revenue (US$ Mn). It includes drivers, restraints and the ongoing trend of the ampoules and syringes market along with their impact on demand during the forecast period.

 
Unilife 3G/A (Passive Acquisition of More Than 5% of Shares)

2017-05-04 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G/A (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(c) ( AMENDMENT 5)     UNILIFE CORPORATION ( NAME OF ISSUER )   Common Stock, par value $0.01 per share (Title of Class of Securities)   90478E301 (CUSIP Number)   April 28, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to des

 
Unilife 3G/A (Passive Acquisition of More Than 5% of Shares)

2017-05-04 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G/A (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(c) ( AMENDMENT 5)     UNILIFE CORPORATION ( NAME OF ISSUER )   Common Stock, par value $0.01 per share (Title of Class of Securities)   90478E301 (CUSIP Number)   April 28, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to des

 
Shutdown Looming: Unilife Files for Chapter 11

2017-04-12 devicespace
KING OF PRUSSIA, Pa., April 12, 2017 /PRNewswire/ -- Unilife Corporation ("Unilife" and together with its domestic subsidiaries, the "Company") (NASDAQ: UNIS; ASX: UNS) today announced that it has commenced a formal proceeding to restructure its balance sheet or to sell its assets as a going concern in order to better position the business for the future.  To facilitate this restructuring or sale, the Company filed voluntary petitions under chapter 11 of the U.

 
Unilife Files for Chapter 11 Protection

2017-04-12 prnewswire
KING OF PRUSSIA, Pa., April 12, 2017 /PRNewswire/ -- Unilife Corporation ("Unilife" and together with its domestic subsidiaries, the "Company") (NASDAQ: UNIS; ASX: UNS) today announced that it has commenced a formal proceeding to restructure its balance sheet or to sell its assets as a going concern in order to better position the business for the future.  To facilitate this restructuring or sale, the Company filed voluntary petitions under chapter 11 of the U.

 
Unilife 3G/A (Passive Acquisition of More Than 5% of Shares)

2017-04-06 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G/A (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(b) ( AMENDMENT 3)     UNILIFE CORPORATION ( NAME OF ISSUER )   Common Stock, par value $0.01 per share (Title of Class of Securities)   90478E103 (CUSIP Number)   DECEMBER 31, 2015 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to

 
The Expectations For West Pharmaceutical Look Hard To Meet

2017-03-17 seekingalpha
West is a strong player in components and delivery systems for injectable pharmaceuticals, a nearly $300 billion market growing at a mid-single digit rate.

 
Unilife RDER

2017-02-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION February 13, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Unilife Corp. File No. 001-34540 - CF#34671 _____________________ Unilife Corp. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on February 9, 2017.

 
Unilife EX-99.1

2017-02-09 sec.gov
EX-99.1 Exhibit 99.1   UNILIFE CORPORATION ARBN 141 042 757 Appendix 4D – Half Year Report Six months ended 31 December 2016 Results for announcement to the market UNILIFE CORPORATION HIGHLIGHTS Results for Announcement to the Market                            Six Months Ended 31 December 2016 US$000’s     Six Months Ended 31 December 2015 US$000’s   Revenues from ordinary activities      Down         47.

 
Unilife FORM 8-K (Current Report/Significant Event)

2017-02-09 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K       CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2017 (February 9, 2017)     UNILIFE CORPORATION (Exact name of Registrant as Specified in Charter)       Delaware   001-34540   27-1049354 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.

 
Unilife UNIS-10Q2-20161231 (Quarterly Report)

2017-02-09 sec.gov
unis-10q_20161231.htm         UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-Q   (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from                      to                      Commission file number 001-34540   UNILIFE CORPORATION (Exact n

 
Unilife FORM SC 13G/A (Passive Acquisition of More Than 5% of Shares)

2017-02-07 sec.gov
Form SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)*     UNILIFE CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 90478E103 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 90478E103